Newsbenzinga
Ultragenyx’s Phase 3 Aspire Study Of Apazunersen Fails Primary And Key Secondary Endpoints In Angelman Syndrome
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…